These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 23345098)

  • 21. Discontinuation of estrogen replacement therapy in GH-treated hypopituitary women alters androgen status and IGF-I.
    Christiansen JJ; Fisker S; Gravholt CH; Bennett P; Svenstrup B; Andersen M; Feldt-Rasmussen U; Christiansen JS; Jørgensen JO
    Eur J Endocrinol; 2005 May; 152(5):719-26. PubMed ID: 15879357
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Efficacy, safety and compliance of long-term growth hormone (GH) replacement therapy in adults with GH deficiency].
    Zaninelli DC; Meister LH; Radominski RB; Borba VZ; Souza AM; Boguszewski CL
    Arq Bras Endocrinol Metabol; 2008 Jul; 52(5):879-88. PubMed ID: 18797596
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term mortality after recombinant growth hormone treatment for isolated growth hormone deficiency or childhood short stature: preliminary report of the French SAGhE study.
    Carel JC; Ecosse E; Landier F; Meguellati-Hakkas D; Kaguelidou F; Rey G; Coste J
    J Clin Endocrinol Metab; 2012 Feb; 97(2):416-25. PubMed ID: 22238382
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Monitoring serum insulin-like growth factor-I (IGF-I), IGF binding protein-3 (IGFBP-3), IGF-I/IGFBP-3 molar ratio and leptin during growth hormone treatment for disordered growth.
    Tillmann V; Patel L; Gill MS; Whatmore AJ; Price DA; Kibirige MS; Wales JK; Clayton PE
    Clin Endocrinol (Oxf); 2000 Sep; 53(3):329-36. PubMed ID: 10971450
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Overall and cause-specific mortality in GH-deficient adults on GH replacement.
    Gaillard RC; Mattsson AF; Akerblad AC; Bengtsson BÅ; Cara J; Feldt-Rasmussen U; Koltowska-Häggström M; Monson JP; Saller B; Wilton P; Abs R
    Eur J Endocrinol; 2012 Jun; 166(6):1069-77. PubMed ID: 22457236
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term safety of recombinant human growth hormone in children.
    Bell J; Parker KL; Swinford RD; Hoffman AR; Maneatis T; Lippe B
    J Clin Endocrinol Metab; 2010 Jan; 95(1):167-77. PubMed ID: 19906787
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Amino acid profiles in adults with growth hormone (GH) deficiency before and during GH replacement therapy.
    Fernholm R; Thoren M; Hoybye C; Anderstam B; Pernow Y; Saaf M; Hall K
    Growth Horm IGF Res; 2009 Jun; 19(3):206-11. PubMed ID: 18990596
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of long-term GH replacement therapy on cardiovascular outcomes in isolated GH deficiency compared with multiple pituitary hormone deficiencies: a sub-analysis from the Dutch National Registry of Growth Hormone Treatment in Adults.
    van Bunderen CC; van den Dries CJ; Heymans MW; Franken AA; Koppeschaar HP; van der Lely AJ; Drent ML
    Eur J Endocrinol; 2014 Aug; 171(2):151-60. PubMed ID: 24801587
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term mortality and causes of death in isolated GHD, ISS, and SGA patients treated with recombinant growth hormone during childhood in Belgium, The Netherlands, and Sweden: preliminary report of 3 countries participating in the EU SAGhE study.
    Sävendahl L; Maes M; Albertsson-Wikland K; Borgström B; Carel JC; Henrard S; Speybroeck N; Thomas M; Zandwijken G; Hokken-Koelega A
    J Clin Endocrinol Metab; 2012 Feb; 97(2):E213-7. PubMed ID: 22238393
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reviewing the safety of GH replacement therapy in adults.
    Stochholm K; Johannsson G
    Growth Horm IGF Res; 2015 Aug; 25(4):149-57. PubMed ID: 26117668
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Incidence of primary cancers and intracranial tumour recurrences in GH-treated and untreated adult hypopituitary patients: analyses from the Hypopituitary Control and Complications Study.
    Child CJ; Conroy D; Zimmermann AG; Woodmansee WW; Erfurth EM; Robison LL
    Eur J Endocrinol; 2015 Jun; 172(6):779-90. PubMed ID: 25810462
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gender difference in insulin-like growth factor I response to growth hormone (GH) treatment in GH-deficient adults: role of sex hormone replacement.
    Span JP; Pieters GF; Sweep CG; Hermus AR; Smals AG
    J Clin Endocrinol Metab; 2000 Mar; 85(3):1121-5. PubMed ID: 10720049
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adult growth hormone (GH)-deficient patients demonstrate heterogeneity between childhood onset and adult onset before and during human GH treatment. Adult Growth Hormone Deficiency Study Group.
    Attanasio AF; Lamberts SW; Matranga AM; Birkett MA; Bates PC; Valk NK; Hilsted J; Bengtsson BA; Strasburger CJ
    J Clin Endocrinol Metab; 1997 Jan; 82(1):82-8. PubMed ID: 8989238
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Body composition and quality of life in adults with growth hormone deficiency; effects of low-dose growth hormone replacement.
    Ahmad AM; Hopkins MT; Thomas J; Ibrahim H; Fraser WD; Vora JP
    Clin Endocrinol (Oxf); 2001 Jun; 54(6):709-17. PubMed ID: 11422104
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Limited efficacy of growth hormone (GH) during transition of GH-deficient patients from adolescence to adulthood: a phase III multicenter, double-blind, randomized two-year trial.
    Mauras N; Pescovitz OH; Allada V; Messig M; Wajnrajch MP; Lippe B;
    J Clin Endocrinol Metab; 2005 Jul; 90(7):3946-55. PubMed ID: 15855257
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum insulin-like growth factor I (IGF-I), IGF-binding proteins 2 and 3, and the risk for development of malignancies in adults with growth hormone (GH) deficiency treated with GH: data from KIMS (Pfizer International Metabolic Database).
    Popovic V; Mattsson AF; Gaillard RC; Wilton P; Koltowska-Häggström M; Ranke MB
    J Clin Endocrinol Metab; 2010 Sep; 95(9):4449-54. PubMed ID: 20610598
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The characteristics of quality of life impairment in adult growth hormone (GH)-deficient survivors of cancer and their response to GH replacement therapy.
    Mukherjee A; Tolhurst-Cleaver S; Ryder WD; Smethurst L; Shalet SM
    J Clin Endocrinol Metab; 2005 Mar; 90(3):1542-9. PubMed ID: 15613427
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Incidence of diabetes mellitus and evolution of glucose parameters in growth hormone-deficient subjects during growth hormone replacement therapy: a long-term observational study.
    Luger A; Mattsson AF; Koltowska-Häggström M; Thunander M; Góth M; Verhelst J; Abs R
    Diabetes Care; 2012 Jan; 35(1):57-62. PubMed ID: 22074727
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reversible Albumin-Binding GH Possesses a Potential Once-Weekly Treatment Profile in Adult Growth Hormone Deficiency.
    Rasmussen MH; Janukonyté J; Klose M; Marina D; Tanvig M; Nielsen LF; Höybye C; Andersen M; Feldt-Rasmussen U; Christiansen JS
    J Clin Endocrinol Metab; 2016 Mar; 101(3):988-98. PubMed ID: 26727076
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An individualized GH dose regimen for long-term GH treatment in Japanese patients with adult GH deficiency.
    Chihara K; Koledova E; Shimatsu A; Kato Y; Kohno H; Tanaka T; Teramoto A; Bates PC; Attanasio AF
    Eur J Endocrinol; 2005 Jul; 153(1):57-65. PubMed ID: 15994746
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.